We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Next-Generation Sequencing (NGS) Market Driven by Launch of Technologically Advanced Systems

By LabMedica International staff writers
Posted on 10 Feb 2023
Print article
Image: The next-generation sequencing (NGS) market is expected to be worth over USD 27 billion by 2027 (Photo courtesy of Pexels)
Image: The next-generation sequencing (NGS) market is expected to be worth over USD 27 billion by 2027 (Photo courtesy of Pexels)

Next generation sequencing (NGS) is a massively parallel sequencing technology that offers scalability, ultra-high throughput, and high speed to determine the order of nucleotides in the entire genome. DNA pre-sequencing is among the most significant steps in the overall sequencing protocol as it involves preparation of sample for the subsequent sequencing reaction. NGS is being gradually integrated into clinical laboratory analysis, testing, and diseases diagnostics in healthcare sectors across the world. The global NGS market is projected to grow at a CAGR of 15.7% from USD 13 billion in 2022 to USD 27 billion by 2027, driven by the launch of technologically advanced NGS systems and improving regulatory and reimbursement scenarios for NGS-based diagnostic tests. However, the end-user budget constraints in developing countries are expected to restrain market growth.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a growth consulting and program management firm.

Based on product & service, the consumables segment dominated the global NGS market in 2021 with the largest share due to the launch of new NGS consumables and demand for reagents and kits. Based on technology, the sequencing by synthesis segment accounted for the largest share of the global NGS market in 2021 due to the launch of new NGS platforms based on sequencing by synthesis technology. Based on application, the diagnostics segment accounted for the largest share of the global NGS market in 2021 due to the increasing demand for NGS based diagnostic products for cancer and noninvasive prenatal testing (NIPT).

Based on end users, the academic institutes & research centers segment dominated the global NGS market in 2021 with the largest share due to a growing number of collaborations between NGS market players and academic & research institutes. Geographically, North America accounted for the largest share of the global NGS market in 2021, driven by the increasing demand for new NGS based diagnostic tools, availability of research funding, and presence of prominent market players in the region.

Related Links:
MarketsandMarkets

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Chagas Disease Test
LIAISON Chagas

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.